Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose
study to assess the safety, tolerability, pharmacokinetic (PK), immunogenicity, and
pharmacodynamic (PD) effects of REGN1500 in patients with a metabolic disorder.